These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1621655)

  • 1. Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda.
    Lepage P; Dabis F; Msellati P; Hitimana DG; Stevens AM; Mukamabano B; Van Goethem C; Van de Perre P
    Am J Dis Child; 1992 May; 146(5):550-5. PubMed ID: 1621655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to measles immunization and the impacts on HIV-infected children.
    Thaithumyanon P; Punnahitananda S; Thisyakorn U; Praisuwanna P; Ruxrungtham K
    Southeast Asian J Trop Med Public Health; 2000 Dec; 31(4):658-62. PubMed ID: 11414407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi.
    Helfand RF; Witte D; Fowlkes A; Garcia P; Yang C; Fudzulani R; Walls L; Bae S; Strebel P; Broadhead R; Bellini WJ; Cutts F
    J Infect Dis; 2008 Nov; 198(10):1457-65. PubMed ID: 18828743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children.
    Mutsaerts EAML; Nunes MC; Bhikha S; Ikulinda BT; Boyce W; Jose L; Koen A; Moultrie A; Cutland CL; Grobbee DE; Klipstein-Grobusch K; Madhi SA
    J Infect Dis; 2019 Sep; 220(9):1529-1538. PubMed ID: 31282539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine.
    Garly ML; Balé C; Martins CL; Monteiro M; George E; Kidd M; Dias F; Aaby P; Whittle HC
    Vaccine; 2001 Feb; 19(15-16):1951-9. PubMed ID: 11228365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi.
    Fowlkes A; Witte D; Beeler J; Audet S; Garcia P; Curns A; Yang C; Fudzulani R; Broadhead R; Bellini WJ; Cutts F; Helfand RF
    J Infect Dis; 2011 Jul; 204 Suppl 1():S149-57. PubMed ID: 21666156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines.
    Markowitz LE; Sepulveda J; Diaz-Ortega JL; Valdespino JL; Albrecht P; Zell ER; Stewart J; Zarate ML; Bernier RH
    N Engl J Med; 1990 Mar; 322(9):580-7. PubMed ID: 2304505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head immunogenicity comparison of Edmonston-Zagreb vs. AIK-C measles vaccine strains in infants aged 8-12 months: A randomized clinical trial.
    Izadi S; Zahraei SM; Salehi M; Mohammadi M; Tabatabaei SM; Mokhtari-Azad T
    Vaccine; 2018 Jan; 36(5):631-636. PubMed ID: 29289382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful immunization of infants at 6 months of age with high dose Edmonston-Zagreb measles vaccine. Cite Soleil/JHU Project Team.
    Job JS; Halsey NA; Boulos R; Holt E; Farrell D; Albrecht P; Brutus JR; Adrien M; Andre J; Chan E
    Pediatr Infect Dis J; 1991 Apr; 10(4):303-11. PubMed ID: 2062626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993.
    Lepage P; Msellati P; Hitimana DG; Bazubagira A; Van Goethem C; Simonon A; Karita E; Dequae-Merchadou L; Van de Perre P; Dabis F
    Pediatr Infect Dis J; 1996 Jun; 15(6):479-85. PubMed ID: 8783343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative serological efficacy of the measles vaccine strains Edmonston-Zagreb, Schwarz and AIK-C in Togolese infants of 4-5 months and 8-10 months].
    Tidjani O; Grunitzky B; Guérin N; Lévy-Bruhl D; Lecam N; Xuereff C; Tatagan K
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):873-84. PubMed ID: 1819435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasa, Zaire.
    Cutts FT; Mandala K; St Louis M; Brown C; Mayala B; Zell ER; Deforest A; Kamenga M; Davachi F; Markowitz LE
    J Infect Dis; 1993 Jun; 167(6):1418-21. PubMed ID: 8501334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire.
    Cutts FT; Nyandu B; Markowitz LE; Forsey T; Zell ER; Othepa O; Wilkins K
    Vaccine; 1994 Nov; 12(14):1311-6. PubMed ID: 7856296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months.
    Tidjani O; Grunitsky B; Guérin N; Lévy-Bruhl D; Lecam N; Xuereff C; Tatagan K
    Lancet; 1989 Dec; 2(8676):1357-60. PubMed ID: 2574304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study.
    Moss WJ; Scott S; Mugala N; Ndhlovu Z; Beeler JA; Audet SA; Ngala M; Mwangala S; Nkonga-Mwangilwa C; Ryon JJ; Monze M; Kasolo F; Quinn TC; Cousens S; Griffin DE; Cutts FT
    J Infect Dis; 2007 Aug; 196(3):347-55. PubMed ID: 17597448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of three measles vaccines in Indian children.
    Banerjee K; Shaikh N; Phadke M; Bedekar SS; Rauta SK; Mehta JM
    Indian J Public Health; 1998; 42(4):113-9. PubMed ID: 10389523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of standard dose Edmonston-Zagreb measles vaccine in highland Papua New Guinean children from four months of age.
    Rogers S; Sanders RC; Alpers MP
    J Trop Med Hyg; 1991 Apr; 94(2):88-91. PubMed ID: 2023293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants.
    Scott S; Moss WJ; Cousens S; Beeler JA; Audet SA; Mugala N; Quinn TC; Griffin DE; Cutts FT
    Clin Infect Dis; 2007 Dec; 45(11):1417-24. PubMed ID: 17990222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) and its determinants: a cohort study in Kigali, Rwanda.
    Lepage P; Van de Perre P; Msellati P; Hitimana DG; Simonon A; Van Goethem C; Mukamabano B; Karita E; Stevens AM; Mathieu G
    Am J Epidemiol; 1993 Mar; 137(6):589-99. PubMed ID: 8470660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles immunity in HIV-infected children.
    Walter EB; Katz SL; Bellini WJ
    Pediatr AIDS HIV Infect; 1994 Oct; 5(5):300-4. PubMed ID: 11361371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.